Corporate Update – Nms (001360.SZ)
Trading Snapshot
- Closing price: CNY 17.88 (unchanged over the 24‑hour period ending 11:19 PM CET on Friday, 23 March).
- Market capitalisation: CNY 3.40 bn.
- Total shares outstanding: 183.5 mn.
- 24‑hour volume: CNY 23.5 mn (approximately 1.38 % of the outstanding share base).
- Year‑to‑date performance: ‑8.25 % since the end of February.
- 200‑day simple moving average: CNY 17.69 – the current price sits just above this support level.
- 52‑week range: CNY 30.98 (high) on 29 January 2026; CNY 12.22 (low) on 21 July 2026.
Market Context
On 22 October the Shanghai Composite fell, yet several constituents reached daily limits, underscoring sector‑specific momentum. Among them, a leading industrial‑equipment manufacturer logged five consecutive limit‑ups—a testament to the sector’s resilience amid a broader sell‑off. Analysts cited supportive policy measures, improving overseas demand, and attractive valuation metrics as catalysts. Nms, operating in adjacent machinery segments, has not mirrored this rally, maintaining a flat trajectory and signalling a more cautious stance.
Related Stocks – 24‑Hour Performance
| Symbol | Current Price | Market Cap | 24‑H Volume | Key Notes |
|---|---|---|---|---|
| 600984.SS – Shaanxi Construction Machi | CNY 3.29 | CNY 566.4 mn | Flat | No change |
| 002412.SZ – Hansen | CNY 7.58 | CNY 4.10 bn | Flat | P/E 16.26 |
| 300889.SZ – Shenzhen Exc‑Led Technolog | CNY 18.20 | CNY 4.10 bn | Flat | No change |
| 300299.SZ – Fuchun Technology | CNY 5.55 | CNY 4.10 bn | Flat | Q1 2026 earnings jump; cost cuts and reduced write‑downs drive profitability |
| 300314.SZ – Ningbo David Medical Device | CNY 14.63 | CNY 4.10 bn | Flat | Q3 2026 revenue & profit surge; focus on innovation and market responsiveness |
Fuchun Technology
- Q1 2026: Revenue up modestly year‑on‑year; net profit surged due to lower promotion costs, reduced receivable write‑downs, and fewer joint‑venture losses.
- Q3 2026: Revenue declined slightly, yet profit rose markedly thanks to tighter cost management.
Ningbo David Medical Device
- Q3 2026: Operating income CNY 1.69 bn (+19.8 %), net profit CNY 5.36 mn (+147.7 %).
- FY 2026 to date: Operating income CNY 4.21 bn (+7.3 %), net profit CNY 7.77 mn (+7.0 %).
- Adjusted net profit fell ~21 % for the first three quarters, but cash flow from operations declined 17 %.
- The company attributes gains to product innovation and rapid market adaptation.
Forward Outlook
While Nms has exhibited price stagnation, its fundamentals remain solid: a moderate market cap, a healthy liquidity position, and a price comfortably above the 200‑day SMA. The firm’s exposure to the broader machinery sector positions it to benefit from the policy‑backed demand lift, provided it can navigate the current earnings slowdown and market volatility.
Investors should monitor:
- Policy Signals – Any new industrial‑equipment subsidies or infrastructure spending announcements.
- Order Book Dynamics – Intra‑day volume spikes or sustained limit‑up pressure may signal a breakout.
- Earnings Guidance – Management’s outlook on profitability and cost control will be critical in restoring investor confidence.
In sum, Nms is currently trading within a narrow band of its long‑term trend. A clear rebound will likely require either a sector‑wide upside or a decisive shift in corporate earnings dynamics.
